TOMSK, Jan 15 – RIA Tomsk. The world's first safe analgesic – thiowurtzine, obtained by changing the CL-20 explosive molecule, developed by a consortium of Tomsk scientists with the participation of chemists of Tomsk State University (TSU) and industrial partners, passed preclinical tests that confirmed its medicinal properties, the press service of TSU said on Wednesday.
Earlier it was reported that Tomsk and Biysk scientists are developing painkillers based on hexaazoisowurtzitane (СL-20) – a substance that is a component of rocket fuel and explosives.
According to the TSU press service, the development of analgesics is carried out within the framework of the federal target program "Pharma 2020" by a scientific group, which includes specialists of the Institute for Problems of Chemical and Energetic Technologies of the Siberian Branch of the RAS (IPCET SB RAS), TSU and Goldberg Research Institute of Pharmacology and Regenerative Medicine Clinic of Tomsk National Research Medical Center (Tomsk NRMC). The industrial partners of the project – are enterprises from the innovative zone of TSU – Sibtermokhim and SPC Chemical Technologies.
"The world's first analgesic based on the first-in-class molecule, low-toxic and without side effects, has successfully passed the preclinical test phase ... The basis for the analgesic, which has no analogues, was the modified powerful explosive molecule CL-20. Preclinical studies have confirmed its unique medicinal properties", – is said in the report.
The new pain relieving medication is called "thiowurtzine". The molecule of its active substance (first-in-class) is obtained by the method of directed synthesis from the CL-20 molecule. Three-year preclinical studies of thiowurtzine were performed in mice, rats, rabbits, guinea pigs and drosophilae. The results showed that in terms of strength and duration of exposure, it surpasses many known analgesics, notes the report.
"The data suggests .. that thiowurtzine does not cause effects characteristic of opioid analgesics – there is no negative effect on the gastrointestinal tract, central nervous system (does not cause the development of euphoria and sedation), it does not inhibit the respiratory center and hematopoietic system. Even after prolonged use, the analgesic does not occur drug dependence and withdrawal syndrome", – an employee of Research Institute of Pharmacology and Regenerative Medicine Clinic Svetlana Krylova is quoted.Now developers have to go through the last and most expensive stage – clinical trials of the drug. The cost of research, giving an objective picture, starts from 0.5 billion rubles. Currently, the creators of thiowurtzine are negotiating with several pharmaceutical companies, including abroad, and are looking for an investor who is ready to finance clinical trials, the message emphasizes.